Substituted imidazo[1,5-a]quinoxalines useful as inhibitors of phosphodiesterase 10 for the treatment of neurological and other disorders

US7875618B2 · kind B2 · utility

Assignees

• Wyeth, LLC · US
• elbion GmbH · DE

Inventors

• Michael S. Malamas · Jamison, US
• Yike Ni · Lexington, US
• James Joseph Erdei · Flourtown, US
• Norbert Höfgen · Radeberg, DE
• Hans Stange · Riesa, DE
• Rudolf Schindler · Dresden, DE
• Ute Egerland · Radebeul, DE
• Barbara Langen · Radebeul, DE

Key dates

• Filing date: Nov 25, 2008
• Grant date: Jan 25, 2011
• Expiry date: Nov 25, 2028

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to imidazo[1,5-a]quinoxaline derivatives having Formula IIa:to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10 (PDE10), as active compounds for treating central nervous system diseases of mammals, including humans.